Predicting skin toxicity according to EGFR polymorphisms in patients with colorectal cancer receiving antibody against EGFR

Monoclonal antibodies against epidermal growth factor receptor (EGFR) can extend progression-free survival (PFS) and overall survival (OS) in patients with unresectable colorectal cancer; however, skin toxicity often interferes with therapy continuation. We analyzed the polymorphisms in EGFR and IgG...

Full description

Saved in:
Bibliographic Details
Published in:Anticancer research 2013-11, Vol.33 (11), p.4995-4998
Main Authors: Saito, Rie, Suzuki, Hideo, Yamada, Takeshi, Endo, Shinji, Moriwaki, Toshikazu, Ueno, Takunori, Hirose, Mitsuaki, Hirai, Sachiko, Yamato, Kenji, Mizokami, Yuji, Hyodo, Ichinosuke
Format: Article
Language:English
Subjects:
Adult
Aged
Aged, 80 and over
Antibodies, Monoclonal - adverse effects
Biomarkers, Tumor - genetics
Colorectal cancer
Colorectal Neoplasms - complications
Colorectal Neoplasms - drug therapy
Colorectal Neoplasms - genetics
Female
Follow-Up Studies
Humans
Male
Middle Aged
Neoplasm Recurrence, Local - complications
Neoplasm Recurrence, Local - drug therapy
Neoplasm Recurrence, Local - genetics
Neoplasm Staging
Polymorphism, Genetic - genetics
Prognosis
Receptor, Epidermal Growth Factor - antagonists & inhibitors
Receptor, Epidermal Growth Factor - genetics
Receptor, Epidermal Growth Factor - metabolism
Receptors, IgG - genetics
Retrospective Studies
Skin Diseases - chemically induced
Skin Diseases - genetics
Skin Diseases - mortality
Survival Rate
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Monoclonal antibodies against epidermal growth factor receptor (EGFR) can extend progression-free survival (PFS) and overall survival (OS) in patients with unresectable colorectal cancer; however, skin toxicity often interferes with therapy continuation. We analyzed the polymorphisms in EGFR and IgG fragment C receptor (FCGR) genes and determined their associations with clinical outcomes including PFS, OS, and skin toxicity. Five polymorphisms in EGFR and FCGR genes in 32 patients with unresectable colorectal cancer who were treated with antibodies against EGFR were examined. Patients carrying the C/C genotype of the EGFR D994D polymorphism displayed significantly less skin toxicity than those with other genotypes, although no significant differences in PFS and OS were noted and no significant interactions were detected for other gene polymorphisms. These results suggest that the EGFR D994D polymorphism is a useful biomarker for predicting the severity of skin toxicity in patients receiving antibody against EGFR.
ISSN:0250-7005
1791-7530